Navigation Links
Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
Date:4/24/2013

rgic asthma" by Kai-Michael Beeh , MD, et al. The article was selected for comment by the JACI Editors ("The Editors' Choice") under the heading "Get the balance right - therapeutic immune modulation in patients with allergic asthma".

Financial Results

Three-month period from January 1 to March 31, 2013

On March 31, 2013, funds available for financing the operations (including cash, cash equivalents, financial assets and trade and other receivables) amounted to CHF 23.58 million. The funds were CHF 5.07 million less than on December 31, 2012 (CHF 28.65 million) primarily due to expenses incurred in ongoing operating activities.

On March 31, 2013, the nominal value of convertible bonds not held by the Company amounted to CHF 13.17 million. Cytos did not buy back any convertible bonds on the market during the first quarter of 2013.

Revenue comprising deferred income from licence fees paid by Novartis of CHF 0.25 million has been recognized in the first quarter 2013, unchanged from the first quarter 2012.

The gross cash burn for operating activities, as calculated on the cash flow statement, was CHF 1.72 million on average per month in the first three months of 2013, compared to CHF 1.04 million on average per month in the first quarter of 2012.

Financial summary (IFRS, consolidated)

(in CHF million) Q1 2013 Q1 2012 Revenue 0,3 0,3 Net operating cost (4,0) (3,0) Operating loss (3,7) (2,8) Net (loss) / income (5,4) 2,5 Net (loss) / income per share (in CHF) (0,24) 0,47 December 31, (in CHF million) March 31, 2013 2012 Cash, cash equivalents, financial assets as well as trade and other receivables 23,6 28,7 Full-time equivalents 22,5 20,9

The detailed Q1 Financial Report 2013 can be downloaded at

http://www.cytos.com/uploads/2013/Cytos_Quarter_1_2013_E.pdf
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. Cytos Biotechnology Strengthens Management Team
3. Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility
4. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
5. Choose New Jersey and Partners to Promote New Jersey As Global Life Science Hub at Worlds Largest Biotechnology Event
6. Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products
7. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
8. NanoSight, One of the UKs Fastest Growing Biotechnology Companies, Wins a 2013 Queens Award for Enterprise - Innovation
9. Global Biotechnology Industry Market Research Report Now Available from IBISWorld
10. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
11. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 29, 2015 Research ... addition of the "Biotechnology for the Non-Biotechnologist" ... for the Non-Biotechnologist, ideal for non-Scientists and Scientists ... and potential of biotechnology. Ideal for ... theory, principles, techniques, and potential of biotechnology ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... , , SOUTHAMPTON, Pa., Jan. 11 Argyce ... http://www.genaera.com , will divest the remaining drug development program ... Trust is soliciting bids to be received no later than ... separately or in combination. Any person interested in purchasing the ...
... BOSTON, Jan. 11 PAREXEL International Corporation (Nasdaq: PRXL ... quarter of Fiscal Year 2010 ended December 31, 2009, and ... The Company,s updated financial guidance takes into account the ... revised expectations for the amount and timing of a previously ...
... ... Screening analysis. , ... 11, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and ... has experienced unprecedented industry adoption with 7 out of the 25 leading pharmaceutical companies ...
Cached Biology Technology:Genaera Liquidating Trust To Sell Remaining Proprietary Assets 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 2Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies 3
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
Spastin (Sp 3G11/1)...
mCD-1 10 transcription reactions...
... Maintenance 112 days/each , ... injections x5 /each , Test ... Production bleed (25 ml blood =12 ml serum) ... blood (~50 ml serum) x1 each , free ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
Biology Products: